您的位置： 百康网 > 期刊 > 肿瘤学 > 《临床肿瘤学医学期刊》 > 2005年 > 2005年7月第7期 ·07/06/15 Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers ·07/06/15 Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As ·07/06/15 Efficacy of Prophylactic Mastectomy in Women With Unilateral Breast Cancer: A Cancer Research Network Project ·07/06/15 Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Pa ·07/06/15 Interventions to Enhance Physical and Psychological Functioning Among Younger Women Who Are Ending Nonhormonal Adjuvant Treatment for Early-Stage Breast Cancer ·07/06/15 Morbidity After Sentinel Lymph Node Biopsy in Primary Breast Cancer: Results From a Randomized Controlled Trial ·07/06/15 Improved Detection of Prostate Cancer Using Classification and Regression Tree Analysis ·07/06/15 Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival ·07/06/15 Survival After Recurrence of Ewing’s Sarcoma Family of Tumors ·07/06/15 Soft Tissue Sarcoma or Malignant Mesenchymal Tumors in the First Year of Life: Experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee ·07/06/15 Prognostic Factors and Outcome of Human Herpesvirus 8–Associated Primary Effusion Lymphoma in Patients With AIDS ·07/06/15 Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma ·07/06/15 Fertility Preservation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian Stimulation With Tamoxifen and Letrozole for Embryo Cryopreservation ·07/06/15 Extent of Damage and Repair in the p53 Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predi ·07/06/15 Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma ·07/06/15 Quality of Life of Long-Term Survivors of Breast Cancer and Lymphoma Treated With Standard-Dose Chemotherapy or Local Therapy ·07/06/15 Outcome of Cancer Patients Considered for Intensive Care Unit Admission: A Hospital-Wide Prospective Study ·07/06/15 Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand ·07/06/15 AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre–Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemothera ·07/06/15 The Ubiquitin-Proteasome Pathway and Its Role in Cancer ·07/06/15 Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer ·07/06/15 Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer ·07/06/15 Molecular Analysis of Familial Endometrial Carcinoma: A Manifestation of Hereditary Nonpolyposis Colorectal Cancer or a Separate Syndrome ·07/06/15 Quality of Life Outcomes From a Randomized Phase III Trial of Cisplatin With or Without Topotecan in Advanced Carcinoma of the Cervix: A Gynecologic Oncology Group Study ·07/06/15 Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study ·07/06/15 Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group ·07/06/15 Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma ·07/06/15 Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission Tomography ·07/06/15 Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenstrm's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Prop ·07/06/15 Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131–Labeled Murine Anti-CD30 Monoclonal Antibody ·07/06/15 Agreement Between Self-Reported Breast Cancer Treatment and Medical Records in a Population-Based Breast Cancer Family Registry ·07/06/15 Hormone Receptor Status of a Contralateral Breast Cancer Is Independent of the Receptor Status of the First Primary in Patients Not Receiving Adjuvant Tamoxifen ·07/06/15 Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response t ·07/06/15 Immunohistochemistry Identifies Carriers of Mismatch Repair Gene Defects Causing Hereditary Nonpolyposis Colorectal Cancer ·07/06/15 Genetic Services for Familial Cancer Patients: A Follow-Up Survey of National Cancer Institute Cancer Centers 首 页　上一页 下一页 尾 页　页次：[nowpage]/[countpage]页　[maxpage]篇/页　共 41 篇　转到第 页

栏目导航 ·2005年1月第1期 ·2005年2月第2期 ·2005年3月第3期 ·2005年4月第4期 ·2005年5月第5期 ·2005年6月第6期 ·2005年7月第7期 ·2005年8月第8期 ·2005年9月第9期 ·2005年10月第10期 ·2005年11月第11期 ·2005年12月第12期